DaVita stock holds a solid valuation as investors digest recent earnings and ratings
Published on 08/22/2026 at 13:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
DaVita Inc. (US23918K1088) stock is drawing investor attention on August 22, 2026 as recent data show the dialysis provider valued at $9.693 billion and trading at a price-to-earnings ratio of 13.86, underscoring a moderate earnings multiple for the kidney-care specialist. Per a market-data overview updated this year, the company’s market capitalization stands at $9.693 billion and the PE ratio at 13.86, framing DaVita as a sizeable but not overextended player in the US healthcare sector. For investors, that combination of scale and a mid-teens earnings multiple sets the stage for a nuanced view on growth versus value.
Valuation snapshot and market backdrop
Recent valuation figures show DaVita’s $9.693 billion market cap as of a 2025 update, positioning the company firmly in the mid- to large-cap bracket in US healthcare services. The same overview cites a PE ratio of 13.86, signaling that the shares are priced at just under 14 times trailing earnings. In simple terms, this level is below many high-growth healthcare names, suggesting investors are paying a moderate premium for DaVita’s profitability and cash flow rather than a lofty growth story.
For context, a PE ratio of 13.86 means that for every $1 of earnings generated over the relevant reporting period, the market is assigning $13.86 in equity value. Compared with higher-multiple diagnostic or biotech stocks that can trade at 25 to 30 times earnings or more, DaVita’s valuation appears relatively restrained, even as its kidney-care services provide recurring revenue tied to chronic disease management. This gap between DaVita’s earnings multiple and that of more aggressively valued healthcare peers offers a numerical illustration of how investors differentiate stable service businesses from faster-growing but more volatile segments.
Price targets and consensus rating context
Beyond raw valuation, recent coverage highlights a clear picture of how the analyst community currently views DaVita. According to data compiled in an August 22, 2026 update, DaVita carries an average rating of Hold alongside an average price target of $221.75. That target level, in triple digits, sits well above many historical trading ranges, underscoring that despite a cautious Hold stance, the consensus sees meaningful upside potential over the coming 12 months relative to recent valuation markers.
The Hold rating signals that analysts collectively see DaVita as fairly valued on a risk-adjusted basis at current levels, neither warranting broad-based accumulation nor aggressive selling. However, the average price target of $221.75 introduces a quantified comparison: if the shares trade at levels consistent with a $9.693 billion market cap and a PE of 13.86, then reaching $221.75 would imply a significant percentage gain from those underlying metrics. This contrast between a neutral rating and a numerically strong target price suggests a tension in the market narrative, where earnings quality and cash flow are seen as supportive, yet sector risks and reimbursement dynamics keep enthusiasm in check.
Earnings, margins and historical performance
In the most recent coverage surrounding DaVita, attention has centered on how earnings and margins evolved in the latest quarter. Reporting in early August 2026 highlighted that DaVita delivered second quarter results that exceeded consensus earnings expectations, with an earnings beat on the headline figures. At the same time, commentary pointed to margin compression compared to the prior-year period, reflecting higher operating costs and an evolving payer mix.
This combination of an earnings beat and margin pressure is instructive for investors. On one hand, the ability to post results above analyst forecasts supports the case for operational resilience, particularly in a business where treatment volumes are relatively stable and tied to chronic conditions. On the other hand, year-over-year margin declines quantify the cost-side challenges that dialysis providers face, whether from staffing expenses, regulatory requirements or shifts in reimbursement rates. Even without the exact margin percentage disclosed in the latest brief, the narrative is clear: DaVita is delivering solid earnings but must navigate a tighter spread between revenue and operating costs than in previous periods.
Historically, DaVita has generated substantial revenue and net income by serving a large base of patients requiring regular dialysis. Past fiscal-year reports, such as those covering 2023 and earlier, documented multi-billion-dollar revenue streams and consistent cash generation. However, those older figures now serve primarily as historical context rather than current metrics, given that a fiscal year ending more than 24 months before August 22, 2026 sits outside the freshness window for evaluating today’s investment case. The relevant takeaway is that DaVita’s core business has long been capable of sustaining high revenue levels; the current focus is on how recent quarters evolve from that base.
Balance between growth and risk
The mid-teens PE ratio and the Hold rating together highlight how the market balances DaVita’s growth prospects with perceived risks. A PE of 13.86 is not low enough to suggest deep distress, nor high enough to signal aggressive growth pricing. Instead, it suggests that investors see DaVita as a steady cash generator whose future performance will be shaped largely by policy and reimbursement trends, technological improvements in kidney care, and the broader trajectory of chronic disease prevalence.
From an investor’s standpoint, the numerical gap between the current valuation metrics and the $221.75 average price target can function as a yardstick for evaluating whether new information shifts the risk-reward profile. If future quarters show that margins stabilize or improve while patient volumes hold firm, the case for DaVita to move closer to that target could be strengthened. Conversely, if cost pressures intensify or regulatory changes constrain reimbursement more than expected, the Hold rating might evolve toward a more cautious stance, with analysts revising their target numbers downward.
Kidney-care business model and services
DaVita’s fundamental business revolves around providing dialysis services and related kidney care to patients suffering from chronic kidney disease and end-stage renal disease. The company operates treatment centers, manages clinical staff and coordinates care with physicians and payers, making it a critical link in the healthcare chain for patients whose kidneys can no longer adequately filter blood. These services are typically delivered multiple times per week, creating a recurring revenue pattern that has historically supported DaVita’s multi-billion-dollar topline.
Alongside dialysis treatments, DaVita has expanded into broader kidney-care management, working to improve outcomes through education, early intervention and collaboration with healthcare providers. This model aims to reduce hospitalizations and enhance quality of life for patients, while helping payers manage the long-term costs associated with chronic kidney disease. In recent years, such efforts have been framed as part of a shift toward value-based care, where reimbursement is tied more closely to outcomes and cost efficiency than simple volume.
Representative product and patient offering
One representative offering within DaVita’s portfolio is its in-center hemodialysis service, which remains a cornerstone of care for many patients. In-center hemodialysis involves patients visiting a DaVita facility several times a week to have their blood filtered through a dialysis machine, under the supervision of trained clinical staff. The service is structured to ensure consistent treatment schedules, monitoring of patient vitals and ongoing adjustment of care plans based on individual needs.
For patients and caregivers, the key attributes of such a service are reliability, clinical quality and convenience. DaVita’s national network of centers aims to provide accessible locations, standardized protocols and integrated support, from nursing staff to dietitians and social workers. As the company explores home-based dialysis options and digital tools to support remote monitoring, the in-center hemodialysis product continues to anchor its financial performance, contributing meaningfully to the revenue streams that underpin the $9.693 billion market cap and the current earnings profile.
Closing view on DaVita stock
Against this backdrop, DaVita stock stands at a moderate valuation with a $9.693 billion market cap and a PE ratio of 13.86, as reflected in recent market-data compilations. While the exact latest share price is not cited in the available sources, the established valuation metrics and the analyst consensus Hold rating with a $221.75 average price target provide a clear numerical framework for assessing the shares as of August 22, 2026. For US retail investors, the story is one of stable kidney-care operations, earnings resilience tempered by margin pressure, and a valuation that leaves room for debate over how future quarters will shift the balance between risk and reward.
Fact box
Company: DaVita Inc.
ISIN: US23918K1088
Ticker: DVA
Exchange: US listing (healthcare services)
Market cap: $9.693 billion (as of a 2025 market-data update)
Sector / Industry: Healthcare services - dialysis and kidney care
Index membership: US large- and mid-cap healthcare universe
